Using the sensitive technology of NGS, comparing biopsy with resection, we describe for the first time substantial loss and gain of EGFR pathway mutations (mainly KRAS) in locally advanced rectal cancer undergoing pre-operative CRT. This evidence concerns the gene KRAS and rectal cancer.